3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Melanoma
32
Hodgkin Disease
29
Lymphoma
10
Sarcoma
7
Uveal Melanoma
5
Neoplasm Metastasis
4
Neoplasms
3
Leiomyosarcoma
2
HIV Infections
2
Solitary Fibrous Tumors
1
Solid Tumor
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neurofibrosarcoma
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Lymphoma, T-Cell, Peripheral
1
Immunotherapy
1
Hyperthermia
1
Hematologic Diseases
1
Carcinoma
1
Advanced Melanoma
1
Acquired Immunodeficiency Syndrome
1
AIDS-Related Complex
1
Interventions
Diathermy
5
Radiotherapy
2
Immunotherapy
2
Immune Checkpoint Inhibitors
2
Cisplatin
2
tislelizumab
1
sodium thiosulfate
1
anlotinib
1
Surgical Procedures, Operative
1
Radiation Dose Hypofractionation
1
Radiation
1
Laparotomy
1
Ifosfamide
1
Fluorouracil
1
Drug Therapy
1
Doxorubicin
1
Docetaxel
1
Dacarbazine
1
Cytoreduction Surgical Procedures
1
Chemoradiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hyperthermia
×
Dacarbazine
×
Clear all
NCT06835049
2025-12-30
TNT-HYPE
Swiss Cancer Institute
Phase 2
Recruiting
24 enrolled